17-AAG
(tanespimycin)Phase 3Small molecule
Bristol-Myers SquibbTanespimycin is an experimental cancer drug that works by blocking a protein called HSP90, which helps cancer cells survive and grow. It is being studied in clinical trials to treat various types of cancer.[1] 17-AAG is currently being investigated across 21 indications[3], with its most advanced program in Phase 3.[1]
17-AAG is one of 529 small molecule programs targeting Follicular Thyroid Carcinoma. It is currently in Phase 3.
21
Indications
33
Total Trials
0
Active Trials
528
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 21 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
117-AAG
Bristol-Myers SquibbPhase 3
Adriamycin
GGynecologic Oncology Group
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
MS Contin
Merck & Co.Preclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Acupan
YYonsei University
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lymphoma4 trials
Leukemia2 trials
Chronic Myelogenous Leukemia2 trials
Breast Cancer2 trials
19 more indications
Melanoma2 trials
Unresectable Solid Tumor2 trials
Advanced Solid Tumors1 trial
Clinical Trial1 trial
Gemcitabine1 trial
Patients With Solid Tumors1 trial
Locally Advanced or Metastatic Solid Tumors1 trial
Thyroid Cancer1 trial
Systemic Mastocytosis1 trial
Patients With Advanced Solid Tumors1 trial
Metastatic Solid Tumors1 trial
Metastatic Prostate Cancer1 trial
Kidney Cancer1 trial
Pancreatic Cancer1 trial
Chronic Lymphocytic Leukemia1 trial
Relapsed or Refractory1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tanespimycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Heat Shock Protein HSP90 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company